Association of polymorphism within the interleukin-28 receptor alpha gene, but not in interleukin-28B, with lower urinary tract symptoms (LUTS) in Chinese

Genetics and Molecular Research

Volumn 14, Issue 3, 2015, Pages 10682-10691

  Xiao, L ^a   Gao, L B ^b   Wei, Q ^c  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

Benign prostatic hyperplasia; Interleukin 28B; Interleukin 28B receptor ; Lower urinary tract symptoms; Single nucleotide polymorphism

Indexed keywords

GENOMIC DNA; INTERLEUKIN 28B; CYTOKINE RECEPTOR; IFNLR1 PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERLEUKIN 28 RECEPTOR ALPHA GENE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PROSTATE HYPERTROPHY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; AGED; ALLELE; ASIAN CONTINENTAL ANCESTRY GROUP; CASE CONTROL STUDY; ETHNOLOGY; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENE EXPRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKINS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE; PROSTATIC HYPERPLASIA; RECEPTORS, CYTOKINE;

EID: 84941357351     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2015.September.9.8     Document Type: Article

References (33)

1. Arvanitis DA, Lianos E, Soulitzis N, Delakas D, et al. (2004). Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncol. Rep. 12: 1131-1137.
2. Barreiro P, Pineda JA, Rallón N, Naggie S, et al. (2011). Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J. Infect. Dis. 203: 1629-1636.
3. Berry SJ, Coffey DS, Walsh PC and Ewing LL (1984). The development of human benign prostatic hyperplasia with age. J. Urol. 132: 474-479.
4. Bierne H, Travier L, Mahlakõiv T, Tailleux L, et al. (2012). Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta. PLoS One 7: e39080.
5. Chen Q, Carroll HP and Gadina M (2006). The newest interleukins: recent additions to the ever-growing cytokine family. Vitam. Horm. 74: 207-228.
6. Cheng M, Si Y, Yang Y, Liu X, et al. (2012). Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J. Antimicrob. Chemother. 67: 1080-1087.
7. Cui Q, Zhang YX, Su J, Chen X, et al. (2011). Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect. Genet. Evol. 11: 1682-1689.
8. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, et al. (2009). Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun. 10: 125-131.
9. Dumoutier L and Renauld JC (2002). Viral and cellular intedeukin-10 (IL-10)-related cytokines: from structures to functions. Eur. Cytokine Netw.13: 5-15.
10. Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, et al. (2012). Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 93: 644-649.
11. Gu FL, Xia TL and Kong XT (1994). Preliminary study of the frequency of benign prostatic hyperplasia and prostatic cancer in China. Urology 44: 688-691.
12. Homma Y, Kawabe K, Tsukamaoto T, Yamanaka H, et al. (1997). Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the International Prostate Symptom Score. Int. J. Urol. 4: 40-46.
13. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, et al. (2007). Human interferon lambda 21 (IFN2λ1) modulates the Th1 /Th2 response. Genes Immun. 8: 254-261.
14. Kotenko SV (2002). The family of IL-l0-related cytokines and their receptors: related, but to what extent? Cytokine Growth Factor Rev. 13: 223-240.
15. Kotenko SV, Gallagber G, Baurin W, Lewis-Antes A, et al. (2003). IFN2λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4: 69-77.
16. Lampertico P, Viganò M, Cheroni C, Facchetti F, et al. (2012). IL28B polymorphisms predict interferon-related HBs-Ag seroclearance in genotype D HBeAg-negative patients with chronic hepatitis B. Hepatology 57: 890-896.
17. Lasfar A, Lewis-Antes, Smirnov SV, Anantha S, et al. (2006). Characterization of the mouse IFN2lambda ligand 2 receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res. 66: 4468-4477.
18. Li WA, Lewis-Antes A, Huang J, Balan M, et al. (2008). Regulation of apoptosis by type III interferons. Cell Prolif. 41: 960-979.
19. Miller LJ, Fischer KA, Goralnick SJ, Litt M, et al. (2002). Interleukin-10 levels in seminal plasma: implications for chronic prostatitis-chronic pelvic pain syndrome. J. Urol. 167: 753-756.
20. Numasaki M, Tagawa M, Iwata F, Suzuki T, et al. (2007). IL228 elicits antitumor responses against murine fibrosarcoma. J. Immunol. 178: 5086-5098.
21. Osaki R, Nishimura T, Shioya M, Takeuchi T, et al. (2012). Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection. Mol. Med. Rep. 5: 525-528.
22. Rauch A, Kutalik Z, Descombes P, Cai T, et al. (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138: 1338-1345.
23. Renauld JC (2003). Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat. Rev. Immunol. 3: 667-676.
24. Robek MD, Boyd BS and Chisari FV (2005). Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 79: 3851-3854.
25. Rowhrborm CG and McConnell JD (2002). Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Campbell's Urology (Walsh PC, Retik AB, Vaughan ED Jr and Wein AJ, eds.). W.B. Saunders Company, Philadelphia 1297-1330.
26. Sato A, Ohtsuki M, Hata M, Kobayashi E, et al. (2006). Antitumor activity of IFN2λ in murine tumor models. J. Immunol. 176: 7686-7694.
27. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, et al. (2007). Inflammation and chronic prostatic diseases: evidence for a link? Eur. Urol. 52: 964-972.
28. Sheppard P, Kindsvogel W, Xu W, Henderson K, et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4: 63-68.
29. Shoskes DA, Albakri Q, Thomas K and Cook D (2002). Cytokine polymorphisms in men with chronic prostatitis/ chronic pelvic pain syndrome: association with diagnosis and treatment response. J. Urol. 168: 331-335.
30. Siebler J, Wirtz S, Weigmann B, Atreya I, et al. (2007). IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. Gastroenterology 132: 358-371.
31. Vilcek J (2003). Novel interferons. Nat. Immunol. 4: 8-9.
32. Wu JP and Gu FL (1991). The prostate in eunuchs. Prog. Clin. Biol. Res. 370: 249-255.
33. Zitzmann K, Brand S, Baehs S, Göke B, et al. (2006). Novel interferonλs induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys. Res. Commun. 344: 1334-1341.